Joe Y. Chang, M.D., Ph.D.

Peer-Reviewed Articles

1. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. PMID: 37478883.
2. Chun SG, Rimner A, Amini A, Chang JY, Donington J, Edelman MJ, Geng Y, Gubens MA, Higgins KA, Iyengar P, Movsas B, Ning MS, Park HS, Rodrigues G, Wolf A, Simone CB. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncol 9(7):971-980, 2023. PMID: 37186595.
3. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
4. Wu Y, Verma V, Gay CM, Chen Y, Liang F, Lin Q, Wang J, Zhang W, Hui Z, Zhao M, Wang J, Chang JY. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Cancer 129(13):1969-1985, 2023. e-Pub 2023. PMID: 36994945.
5. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw 21(4):340-350, 2023. PMID: 37015337.
6. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. PMID: 36716413.
7. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys 114(5):977-988, 2022. e-Pub 2022. PMID: 35675852.
8. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
9. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys 114(5):977-988, 2022. PMID: 35675852.
10. Wu Y, Verma V, Liang F, Lin Q, Zhou Z, Wang Z, Wang Y, Wang J, Chang JY. Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 114(4):635-644, 2022. e-Pub 2022. PMID: 35196537.
11. Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol 176:149-156, 2022. e-Pub 2022. PMID: 36209942.
12. Kim H, Venkatesulu BP, McMillan MT, Verma V, Lin SH, Chang JY, Welsh JW. Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys 114(4):676-683, 2022. e-Pub 2022. PMID: 35973624.
13. Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol 23(10):1321-1331, 2022. e-Pub 2022. PMID: 36087590.
14. Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang Z, Chen M, Ma S, Xie C, Xu Y, Li J, Ge H, Liu A, Zhao L, Rao C, Xie C, Bi N, Hui Z, Zhu G, Yuan Z, Wang J, Zhao L, Zhou W, Rim CH, Navarro-Martin A, Vanneste BGL, Ruysscher D, Choi JI, Jassem J, Chang JY, Kepka L, Käsmann L, Milano MT, Van Houtte P, Suwinski R, Traverso A, Doi H, Suh YG, Noël G, Tomita N, Kowalchuk RO, Sio TT, Li B, Lu B, Fu X.. International consensus on radiotherapy in metastatic non-small cell lung cancer. Transl Lung Cancer Res 11(9):1763-1795, 2022. PMID: 36248338.
15. Chen M, Wang Z, Jiang S, Sun J, Wang L, Sahoo N, Brandon Gunn G, Frank SJ, Xu C, Chen J, Nguyen QN, Chang JY, Liao Z, Ronald Zhu X, Zhang X. Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Sci Rep 12(1):9178, 2022. e-Pub 2022. PMID: 35655073.
16. Chen M, Wang Z, Jiang S, Sun J, Wang L, Sahoo N, Brandon Gunn G, Frank SJ, Xu C, Chen J, Nguyen QN, Chang JY, Liao Z, Ronald Zhu X, Zhang X. Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. Sci Rep 12(1):9178, 2022. PMID: 35655073.
17. Chang JY and Verma V. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival. JNCCN 20(5):531-539, 2022. PMID: 35545175.
18. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(5):497-530, 2022. PMID: 35545176.
19. Chang JY, Verma V, Welsh JW, Formenti SC. Radiotherapy plus immune checkpoint blockade in PD(L)-1 resistant metastatic NSCLC. Lancet Oncol 23(4):e156, 2022. PMID: 35358456.
20. Vassiliev ON, Peterson CB, Chang JY, Mohan R. Monte Carlo evaluation of target dose coverage in lung stereotactic body radiation therapy with flattening filter-free beams. J Radiother Pract 21(1):81-87, 2022. e-Pub 2020. PMID: 35401050.
21. Chang JY, Verma V, Weichselbaum RR. Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers: Let's Not Forget Radiotherapy. JAMA Oncol 8(3):333-334, 2022. PMID: 34989790.
22. Knopf AC, Czerska K, Fracchiolla F, Graeff C, Molinelli S, Rinaldi I, Rucincki A, Sterpin E, Stützer K, Trnkova P, Zhang Y, Chang JY, Giap H, Liu W, Schild SE, Simone CB, Lomax AJ, Meijers A.. Clinical necessity of multi-image based (4D MIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy - A comprehensive review. Radiother Oncol(169):77-85, 2022. PMID: 35189152.
23. De Leo AN, Dagan R, Amdur RJ, Yeung AR, Li J, Brooks ED, Gilbo P, Gomez D, Chang JY, Ning M.. How Three Academic Centers Prescribe SBRT for Primary Lung Cancer. Pract Radiat Oncol, 2022. PMID: 35219881.
24. Brooks, ED, Wang, X, De, B, Verma, V, Williamson, TD, Hunter, R, Mohamed, ASR, Ning, MS, Zhang, X, Chang, JY. An Algorithm for Thoracic Re-Irradiation Using Biologically Effective Dose: A Common Language on How to Treat in a “No-Treat Zone”. Radiation Oncology 17(1):10.1186/s13014-021-01977-1, 2022. e-Pub 2022. PMID: 34991637.
25. Li H, Dong L, Bert C, Chang J, Flampouri S, Jee KW, Lin L, Moyers M, Mori S, Rottmann J, Tryggestad E, Vedam S.. AAPM Task Group Report 290: Respiratory motion management for particle therapy. Med Phys, 2022. PMID: 35066871.
26. Seyedin SN, Bassalow R, Mawlawi OR, Turner LM, Patel RR, Mazin SR, Oderinde OM, Voronenko Y, Wages CA, Olcott PD, Chang JY, Balter PA, Welsh JW. The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study. Front Oncol 12:921473, 2022. e-Pub 2022. PMID: 36313653.
27. Chang JY, Verma V, Feng L, Roth JA. SABR for operable stage I non-small-cell lung cancer: comparison to surgery. Lancet Oncol 22(12):e537-e538, 2021. PMID: 34856147.
28. Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V.. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol 64(4):403-408, 2021. PMID: 34913815.
29. Chuong MD, Hallemeier CL, Li H, Zhu XR, Zhang X, Tryggestad EJ, Yu J, Yang M, Choi JI, Kang M, Liu W, Knopf A, Meijers A, Molitoris JK, Apisarnthanarax S, Giap H, Hoppe BS, Lee P, Chang JY, Simone CB, Lin SH.. Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Front Oncol 11:748331, 2021.
30. Amini A, Verma V, Simone CB 2nd, Chetty IJ, Chun SG, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Rybkin II, Slotman BJ, Wolf A, Chang JY.. American Radium Society™ Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. e-Pub 2021. PMID: 34571054.
31. Alshawa A, Cadena AP, Stephen B, Reddy A, Mendoza TR, McQuinn L, Lawhorn K, Zarifa A, Bernhardt AM, Fessaheye S, Warneke CL, Chang JY, Naing A. Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial. Invest New Drugs 39(4):1113-1122, 2021. e-Pub 2021. PMID: 33580845.
32. Iyengar P, Zhang-Velten E, Court L, Westover K, Yan Y, Lin MH, Xiong Z, Patel M, Rivera D, Chang JY, Saunders M, Shivnani A, Lee A, Hughes R, Gerber D, Dowell J, Gao A, Heinzerling J, Li Y, Ahn C, Choy H, Timmerman R.. Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. JAMA Oncol, 2021. PMID: 34383006.
33. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67. e-Pub 2021. PMID: 34237343.
34. Chang JY. When constrained by constraints: Thinking outside of the box in both technology and biology. Int J Radiat Oncol Biol Phys 110(2):266-267, 2021. PMID: 33989570.
35. Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
36. Ning MS, Das P, Rosenthal DI, Dabaja BS, Liao Z, Chang JY, Gomez DR, Klopp AH, Gunn GB, Allen PK, Nitsch PL, Natter RB, Briere TM, Herman JM, Wells R, Koong AC, McAleer MF. Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. J Natl Compr Canc Netw:1-9. e-Pub 2021. PMID: 33878727.
37. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw 19(3):254-266, 2021. e-Pub 2021. PMID: 33668021.
38. Patel RR, Verma V, Barsoumian HB, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez MA, Welsh JW. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys 109(2):352-364, 2021. e-Pub 2020. PMID: 32798606.
39. Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer. e-Pub 2021. PMID: 33707003.
40. Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 5(S2213-2600):467-475, 2021. PMID: 33096027.
41. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2020. PMID: 33198942.
42. Anas Alshawa A, Cadena AP, Stephen B, Reddy A, Mendoza TR, McQuinn L, Lawhorn K, Zarifa A, Maximilian A, Bernhardt AM, Fessaheye S, Warneke CL, Chang JY, Naing A. Effects of Glutamine for Prevention of Radiation-Induced Esophagitis: A Double-Blind Placebo-Controlled Trial. Investigational New Drugs, 2021. e-Pub 2021. PMID: PMID: 33580845.
43. Chang JY, Mehran RZ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O’Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, on behalf of The STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncology 22(10):1448-1457, 2021. PMID: 34529930.
44. Farooqi A, Ludmir EB, Mitchell KG, Antonoff MB, Tang C, Lee P, Chang J, Elamin Y, Gomez DR, Gandhi SJ. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiother Oncol 163:114-118, 2021. PMID: 34419505.
45. Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW.. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol 31(3):217-226, 2021. PMID: 34090648.
46. Chun SG, Simone CB 2nd, Amini A, Chetty IJ, Donington J, Edelman MJ, Higgins KA, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society™ Appropriate Use Criteria: Radiation Therapy for Limited-stage Small Cell Lung Cancer 2020. J Thorac Oncol(S1556-0864), 2020. PMID: 33166720.
47. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 8(2), 2020. PMID: 33051340.
48. Higgins KA, Simone CB 2nd, Amini A, Chetty IJ, Donington J, Edelman MJ, Chun SG, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. J Thorac Oncol(S1556-0864), 2020. PMID: 33011389.
49. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. e-Pub 2020. PMID: 32916308.
50. Patel RR, Verma V, Barsoumian H, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez AM, Welsh JW.. Use of Multi-Site Radiation Therapy as Systemic Therapy: A New Treatment Approach Personalized by Patient Immune Status. Int J Radiat Oncol Biol Phys(S0360-3016), 2020.
51. Simone CB, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol 30(3):253-261, 2020. PMID: 32503791.
52. Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive Management of Presumed Synchronous Early-Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiotherapy. Int J Radiat Oncol Biol Phys 107(2):261-269, 2020. e-Pub 2020. PMID: 32044413.
53. Ai X, Cai Y, Chu Q, Han C, Lu Y, Qin S, Wu L, Xie C, Yuan Z, Zhong W, Zhu X, Chang JY, Zhu Z. Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics. Zhongguo Fei Ai Za Zhi 23(6):532-540, 2020. PMID: 32517461.
54. Nassiliev ON, Peterson CB, Chang JY, Mohan R. Using FFF beams to improve the therapeutic ratio of lung SBRT. Journal of Radiotherapy in Practice, 2020.
55. Wang Z, Chen M, Sun J, Jiang S, Wang L, Wang X, Sahoo N, Gunn GB, Frank SJ, Nguyen QN, Liao Z, Chang JY, Zhu XR, Zhang X. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiother Oncol 146:200-204, 2020. e-Pub 2020. PMID: 32220701.
56. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 38(14):1569-1579, 2020. e-Pub 2020. PMID: 32160096.
57. Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH. Clinical and Radiographic Presentations of COVID-19 among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol, 2020. e-Pub 2020. PMID: 32395673.
58. Zeng J, Badiyan SN, Garces YI, Wong T, Zhang X, Simone CB 2nd, Chang JY, Knopf AC, Mori S, Iwata H, Meijers A, Li H, Bues M, Liu W, Schild SE, Rengan R; International Particle Therapy Cooperative Group Thoracic Subcommittee. Consensus Statement on Proton Therapy in Mesothelioma. Pract Radiat Oncol, 2020. e-Pub 2020. PMID: 32461036.
59. Nantavithya C, Gomez DR, Chang JY, Mohamed ASR, Fuller CD, Li H, Brooks ED, Gandhi SJ. An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. Radiother Oncol 145:209-214, 2020. e-Pub 2020. PMID: 32062325.
60. Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open 3(4):e203277, 2020. e-Pub 2020. PMID: 32320035.
61. McGinnis GJ, Ning MS, Nitsch PL, O'Reilly MS, McAleer MF, Koong AC, Chang JY. Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. J Thorac Oncol, 2020. e-Pub 2020. PMID: 32311499.
62. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for non-enrollment: results of a large, prospective, multi-year analysis. Int J Radiat Oncol Biol Phys, 2020. e-Pub 2020. PMID: 32360653.
63. Pasalic D, Betancourt-Cuellar SL, Taku N, Ludmir EB, Lu Y, Allen PK, Tang C, Antonoff MB, Fuller CD, Rosenthal DI, Morrison WH, Phan J, Garden AS, Welsh JW, Chang JY, Liao Z, Erasmus JJ, Nguyen QN. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. e-Pub 2020. PMID: 32129548.
64. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol 15(2):266-273, 2020. e-Pub 2019. PMID: 31605794.
65. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. J Thorac Oncol 15(2):pii: S1556-0864(19)33659-7, 2020. e-Pub 2019. PMID: 31778797.
66. Brooks ED, Verma V, Senan S, De Baere T, Lu S, Brunelli A, Chang JY, International Association for the Study of Lung Cancer Advanced Radiation Technology Committee. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. J Thorac Oncol 15(2):176-189, 2020. e-Pub 2019. PMID: 31712134.
67. Wang XS, Shi Q, Mendoza T, Lin S, Chang JY, Bokhari RH, Lin HK, Garcia-Gonzalez A, Kamal M, Cleeland CS, Liao Z. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys 106(1):100-107, 2020. e-Pub 2019. PMID: 31627177.
68. Kang J, Ning MS, Feng H, Li H, Bahig H, Brooks ED, Welsh JW, Ye R, Miao H, Chang JY. Predicting 5-Year Progression and Survival Outcomes for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys 106(1):90-99, 2020. e-Pub 2019. PMID: 31586665.
69. Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, Skinner HD.. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol, 2020.
70. Zhuang H, Tao L, Wang X, Shi S, Yuan Z, Wang E, Chang JY. Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study. Front Oncol 10:12, 2020. e-Pub 2020. PMID: 32117704.
71. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer 28(S1525-7304), 2020.
72. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
73. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Gettinger S, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW, Martins RG, Otterson GA, Patel SP, Reckamp KL, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer KW, Yang SC, Gregory K, OCN, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw 17(12):1464-1472, 2019. PMID: 31805526.
74. Brooks ED, Verma V, Senan S, De Baere T, Lu S, Brunelli A, Chang JY. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol, 2019. e-Pub 2019. PMID: PMID: 31712134.
75. Brooks ED, Ning MS, Verma V, Zhu XR, Chang JY. Proton therapy for non-small cell lung cancer: the road ahead. Transl Lung Cancer Res 8(S2):202-212, 2019. PMID: 31673525.
76. Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW.. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol, 2019. PMID: 31529018.
77. Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi S, Heymach JV, Chang JY. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Int J Radiat Oncol Biol Phys 20(4):480-488, 2019. PMID: 31078421.
78. Zhuang H, Shi S, Chang JY. Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. Transl Lung Cancer Res 8(4):524-531, 2019. PMID: 31555525.
79. Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH.. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol, 2019. PMID: 31479748.
80. Verma V, Ludmir EB, Mesko SM, Brooks ED, Augustyn A, Milano MT, Lin SH, Chang JY, Welsh JW.. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol, 2019. PMID: 31446147.
81. Brooks ED, Verma V, Chang JY. Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?. Front Oncol, 2019. PMID: 31293978.
82. Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 7(2):199-204, 2019. PMID: 29876319.
83. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 16(2):123-135, 2019. e-Pub 2018. PMID: 30401936.
84. Zhuang H, Shi S, Yuan Z, Chang JY. Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. Mol Cancer 18(1):21, 2019. e-Pub 2019. PMID: 30732625.
85. Verma V, Haque W, Cushman TR, Lin C, Simone CB , Chang JY, McClelland S , Welsh JW. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother 42(2):55-64, 2019.
86. Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol 10:193, 2019. e-Pub 2019. PMID: 30828330.
87. Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD.. Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2018. e-Pub 2018.
88. Yu W, Tang C, Hobbs BP, Li X, Koay EJ, Wistuba II, Sepesi B, Behrens C, Rodriguez Canales J, Parra Cuentas ER, Erasmus JJ, Court LE, Chang JY. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 102(4):1090-1097, 2018. e-Pub 2017. PMID: 29246722.
89. Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, Li A, Younes AI, Cadena A, Cushman TR, Chang JY, Nguyen QN, Gomez DR, Diab A, Heymach JV, Hwu P, Cortez MA, Welsh JW. Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti-PD1-resistant lung tumor model. Clin Cancer Res 24(22):5735-5743, 2018. e-Pub 2018. PMID: 29784675.
90. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, Thomas CR. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer 6(1):128, 2018. e-Pub 2018. PMID: 30470252.
91. Vassiliev ON, Kry SF, Wang HC, Peterson CB, Chang JY, Mohan R. Radiotherapy of lung cancers: FFF beams improve dose coverage at tumor periphery compromised by electronic disequilibrium. Phys Med Biol 63(19):195007, 2018. e-Pub 2018. PMID: 30189421.
92. Verma V, Chang JY. Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy. Transl Lung Cancer Res 7(Suppl 3):S280-S282, 2018. PMID: 30393622.
93. Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 101(3):558-563, 2018. e-Pub 2018. PMID: 29680255.
94. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw 16(7):807-821, 2018. PMID: 30006423.
95. Liu C, Schild SE, Chang JY, Liao Z, Korte S, Shen J, Ding X, Hu Y, Kang Y, Keole SR, Sio TT, Wong WW, Sahoo N, Bues M, Liu W. Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. Int J Radiat Oncol Biol Phys 101(2):479-489, 2018. e-Pub 2018. PMID: 29550033.
96. Li H, Chang JY. Accounting for, Mitigating, and Choice of Margins for Moving Tumors. Semin Radiat Oncol 28(3):194-200, 2018. PMID: 29933879.
97. Zhang Y, Shen J, Simone CB, Cappuzzo F, Fong KM, Rosell R, Chang JY, Ampollini L, Choi JI, He J, Jiang T, Written on behalf of AME Lung Cancer Cooperative Group. How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. J Thorac Dis 10(6):3883-3890, 2018. PMID: 30069390.
98. Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 7(2):199-204, 2018. PMID: 29876319.
99. de Groot PM, Shroff GS, Ahrar J, Sabloff BS, Gladish GM, Moran C, Gupta S, Gladish GW, Chang JY, Erasmus JJ. Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. Adv Radiat Oncol 3(2):139-145, 2018. e-Pub 2017. PMID: 29904738.
100. Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep 8(1):1922, 2018. e-Pub 2018. PMID: 29386574.
101. Kang J, Chang JY, Sun X, Men Y, Zeng H, Hui Z. Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. J Cancer 9(3):584-593, 2018. e-Pub 2018. PMID: 29483964.
102. Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, Paris S, Welsh JW.. Combining radiation plus immunotherapy to improve systemic immune response. J Thorac Dis 10(S3):S468-479, 2018.
103. Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O’Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Network Open 1(4):e181390, 2018.
104. Verma V, Chang JY. Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy. J Thorac Dis(9):S1124-S1126, 2018.
105. Verma V, Sprave T, Haque W, Simone CB 2nd, Chang JY, Welsh JW, Thomas CR Jr.. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer 6(1):128, 2018.
106. Verma V, Chang JY. Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. J Thorac Dis 10(1):21-24, 2018. PMID: 29600013.
107. Moreno AC, Zhang N, Giordano SH, Liao Z, Gomez D, Chang JY, Lin SH.. Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. Int J Part Ther 5(2):18-27, 2018.
108. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017. PMID: 29280461.
109. Chang JY, Zhang X, Knopf A, Li H, Mori S, Dong L, Lu HM, Liu W, Badiyan SN, Both S, Meijers A, Lin L, Flampouri S, Li Z, Umegaki K, Simone CB, Zhu XR. Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. Int J Radiat Oncol Biol Phys 99(1):41-50, 2017. e-Pub 2017. PMID: 28816159.
110. Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer 123(16):3031-3039, 2017. e-Pub 2017. PMID: 28346656.
111. Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol 3(8):e172032, 2017. e-Pub 2017. PMID: 28727865.
112. Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(4):900-907, 2017. e-Pub 2016. PMID: 28258887.
113. Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Onco:S1879-8500(17)30196-0. e-Pub 2017. PMID: 28867546.
114. Chance WW, Nguyen QN, Mehran R, Welsh JW, Gomez DR, Balter P, Komaki R, Liao Z, Chang JY. Stereotactic ablative radiotherapy for adrenal gland metastases: factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol 7(3):e195-e203, 2017. e-Pub 2016. PMID: 27743801.
115. Vial MR, Khan KA, O'Connell O, Peng SA, Gomez DR, Chang JY, Rice DC, Mehran R, Jimenez CJ, Grosu HB, Ost DE, Eapen GA. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients. Ann Thorac Surg 103(5):1600-1605, 2017. e-Pub 2016. PMID: 28027732.
116. Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Zhu XR, Gomez DR, Lin SH, Gillin MT, Komaki RU, Liao Z, Hahn SM, Chang JY. Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy. Int J Radiat Oncol Biol Phys 98(1):222, 2017. PMID: 28586972.
117. Nguyen QN, Lu Y, Tang C, Chance WW, Mehran R, Balter P, Welsh JW, Hahn SM, Jeter MD, Komaki RU, Gomez DR, Chang JY, Liao Z. Stereotactic Ablative Body Radiation for Pulmonary Metastases: Should We Consider Dose Escalation for More Unresponsive Histologies?. Int J Radiat Oncol Biol Phys 98(1):237, 2017. PMID: 28587012.
118. Brooks ED, Micevic G, Chang JY. Development of a Transcriptomic Signature Associated With Lung Adenocarcinoma Recurrence and Survival. Int J Radiat Oncol Biol Phys 98(1):251, 2017. PMID: 28587046.
119. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2016. PMID: 27649551.
120. Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablation Radiotherapy for Isolated Lung Recurrence of Non-Small-Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol 12(6):983-992. e-Pub 2017. PMID: 28259750.
121. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol 12(2):375-382, 2017. e-Pub 2016. PMID: 27794500.
122. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839-850, 2017. e-Pub 2016. PMID: 27821490.
123. Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, O'Reilly M, Jeter M, Gillin M, Zhu X, Zhang X, Mohan R, Swisher S, Hahn S, Cox JD. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol 122(2):274-280, 2017. e-Pub 2017. PMID: 28139305.
124. Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol 7(1):63-71, 2017. e-Pub 2016. PMID: 27637136.
125. Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez D.. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol 125(2):325-330, 2017.
126. Wang Q, Zhou S, Court LE, Verma V, Koay E Zhang L, Zhang W, Chad Tang C, Lin S, Welsh J, Blum M, Betancourt S Dipen M, Hofstetter WL, Chang JY. Radiomics predicts clinical outcome in primary gastroesophageal junction adenocarcinoma treated by chemo/radiotherapy and surgery. Physics & Imaging in Radiation Oncology 3:34-42, 2017. e-Pub 2017.
127. de Groot PM, Shroff GS, Ahrar J, Sabloff BS, Gladish GM, Moran C, S Gupta S, Gladish GW, Chang JY, Erasmus JJ. Implications for high-precision dose radiotherapy planning or limited surgical resection after percutaneous CT-guided lung nodule biopsy using a tract sealant. Advances in Radiation Oncology, 2017. e-Pub 2017.
128. Iyengar P, Westover KD, Court LE, Patel MK, Shivnani AT, Saunders MW, Li Y, Chang JY, Gao A, Ahn C, Choy H, Timmerman RD. A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patients-An Interim Analysis. Int J Radiat Oncol Biol Phys 96(2S):E451, 2016. PMID: 27674727.
129. Wang Q, Zhou S, Court LE, Koay EJ, Zhang L, Zhang W, Lin SH, Tang C, Welsh JW, Hofstetter WL, Chang JY. Risk Stratification Incorporating Complementary Contrast Computed Tomography Texture Features for Prognosis in Primary Gastroesophageal Junction Adenocarcinoma. Int J Radiat Oncol Biol Phys 96(2S):S152-S153, 2016. PMID: 27675655.
130. Tang C, Amer A, Hobbs B, Li X, Behrens C, Para Cuentas E, Rodriguez Canales J, Chang JY, Hong D, Welsh JW, Wistuba I, Koay EJ. Pathology-Based Non-Small Cell Lung Cancer Radiomics Signature Describing the Local Tumor Immune Environment: Discovery and Validation. Int J Radiat Oncol Biol Phys 96(2S):S42-S43, 2016. PMID: 27675926.
131. Wang X, Schoenhals JE, Valdecanas DR, Li A, Ye H, Zhang F, Tang M, Tang C, Liu CG, Liu X, Komaki RU, Gomez DR, Chang JY, Cortez MA, Welsh JW. Suppression of Major Histocompatibility Complex (MHC) Class I and II Mediates Resistance to Anti-PD-1 in Lung Adenocarcinoma Tumors That Can Be Overcome by Radiation Therapy. Int J Radiat Oncol Biol Phys 96(2S):S89, 2016. PMID: 27676044.
132. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. e-Pub 2016. PMID: 27713162.
133. Xu JY, Lu S, Xu XY, Hu SL, Li B, Li WX, Chang JY. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumour Biol 37(8):10349-10356, 2016. e-Pub 2016. PMID: 26846099.
134. Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. Nat Rev Clin Oncol 13(8):516-524, 2016. e-Pub 2016. PMID: 26951040.
135. Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 95(4):1226-1235, 2016. e-Pub 2016. PMID: 27209498.
136. Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J 22(4):257-266, 2016. PMID: 27441745.
137. Selek U, Chang JY. Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. J Thorac Dis 8(7):1394-1397, 2016. PMID: 27500390.
138. Liu W, Schild SE, Chang JY, Liao Z, Chang YH, Wen Z, Shen J, Stoker JB, Ding X, Hu Y, Sahoo N, Herman MG, Vargas C, Keole S, Wong W, Bues M. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys 95(1):523-533, 2016. e-Pub 2015. PMID: 26725727.
139. Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS, International Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 95(1):505-516, 2016. e-Pub 2016. PMID: 27084663.
140. Moghanaki D, Chang JY . Is surgery still the optimal treatment for stage I non-small cell lung cancer?. Transl Lung Cancer Res 5(2):183-189, 2016. PMID: 27183993.
141. Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys 43(3):1111, 2016. PMID: 26936698.
142. Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J 22(2):130-137, 2016. PMID: 27111909.
143. Zhuang H, Zheng Y, Wang J, Chang JY, Wang X, Yuan Z, Wang P. Analysis of risk and predictors of brain radiation necrosis after radiosurgery. Oncotarget 7(7):7773-7779, 2016. e-Pub 2015. PMID: 26675376.
144. Chang JY, Senan S, Smit EF, Roth JA. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer. Lancet Oncology 17(2):e42-e43, 2016. PMID: 26868349.
145. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. e-Pub 2016. PMID: 26891607.
146. Zhuang H, Yuan X, Sun D, Bian J, Chang JY, Yuan Z, Wang P. Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. Oncotarget. e-Pub 2016. PMID: 26933810.
147. Zhuang H, Yuan X, Chang JY, Song Y, Wang J, Yuan Z, Wang X, Wang P. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. e-Pub 2016. PMID: 26934327.
148. Li R, Pu X, Chang JY, Ye Y, Komaki R, Minna JD, Roth JA, Han B, Wu X. MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One 11(3):e0150467, 2016. e-Pub 2016. PMID: 26991123.
149. Zhao L, Pu X, Ye Y, Lu C, Chang JY, Wu X. Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. Cancers (Basel) 8(2), 2016. e-Pub 2016. PMID: 26901225.
150. Zhuang H, Yuan X, Zheng Y, Li X, Chang JY, Wang J, Wang X, Yuan Z, Wang P. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep 6:24364, 2016. e-Pub 2016. PMID: 27067388.
151. Khader J, Al-Mousa A, Hijla FA, Al-Heet S, Rashdan I, Balter P, Chang JY, Wadi-Ramahi S.. Requirements and Implementation of a Lung SBRT Program in a Developing Country: Benefits of International Cooperation. Int J Radiat Oncol Biol Phys 95(4):1236-1238, 2016.
152. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. e-Pub 2015. PMID: 26310908.
153. Grant JD, Shirvani SM, Tang C, Juloori A, Rebueno NC, Allen PK, Chang JY. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. Pract Radiat Oncol 5(4):e383-391, 2015. e-Pub 2015. PMID: 25731965.
154. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 41(6):503-510, 2015. e-Pub 2015. PMID: 25872878.
155. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6):630-637, 2015. e-Pub 2015. PMID: 25981812.
156. Smith BD, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Shirvani SM. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. e-Pub 2015. PMID: 26094172.
157. Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol 115(3):367-372, 2015. e-Pub 2015. PMID: 26028228.
158. Chang JY, Bezjak A, Mornex F, IASLC Advanced Radiation Technology Committee. Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Non-Small-Cell Lung Cancer: What We Have Learned on behalf of the IASLC Advanced Radiation Technology Committee. J Thorac Oncol 10(4):577-585, 2015. e-Pub 2014. PMID: 25514807.
159. Willers H, Stinchcombe TE, Barriger RB, Chetty IJ, Ginsburg ME, Kestin LL, Kumar S, Loo BW, Movsas B, Rimner A, Rosenzweig KE, Videtic GM, Chang JY, Expert Panel on Radiation Oncology-Lung:. ACR Appropriateness Criteria® Induction and Adjuvant Therapy for N2 Non-small-cell Lung Cancer. Am J Clin Oncol 38(2):197-205, 2015. PMID: 25803563.
160. Chang JY. Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer. Semin Radiat Oncol 25(2):110-116, 2015. PMID: 29893286.
161. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non-Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clin Lung Cancer 10(1016):156-163, 2015. e-Pub 2014. PMID: 25467928.
162. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. Int J Radiat Oncol Biol Phys 91(1):149-156, 2015. e-Pub 2014. PMID: 25442335.
163. Li H, Zhang X, Park P, Liu W, Chang JY, Liao Z, Frank S, Li Y, Poenisch F, Mohan R, Gillin M, Zhu R. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol 114(5):367-72, 2015.
164. Chang JY. Stereotactic ablative radiotherapy: aim for a cure of cancer. Ann Transl Med 3(1):12, 2015. PMID: 25705644.
165. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Choy H.. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 93(4):757-764, 2015.
166. Cortez MA, Valdecanas D, Niknam S, Peltier HJ, Diao L, Giri U, Komaki R, Calin GA, Gomez DR, Chang JY, Heymach JV, Bader AG, Welsh JW. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Mol Ther Nucleic Acids 4:e270, 2015. e-Pub 2015. PMID: 26670277.
167. Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancers in the Elderly. JAMA Surg 149(12):1244-1253, 2014. e-Pub 2014. PMID: 25321323.
168. Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, Li Y, Sahoo N, Poenisch F, Gomez DR, Wu R, Gillin M, Zhang X. Clinical implementation of intensity-modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys 90(4):809-818, 2014. e-Pub 2014. PMID: 25260491.
169. Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X. Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer. Clin Pharmacol Ther 96(5):609-615, 2014. e-Pub 2014. PMID: 25054431.
170. Kardar L, Li Y, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol 4(6):e259-e268, 2014. e-Pub 2014. PMID: 25407877.
171. McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys 90(4):819-827, 2014. e-Pub 2014. PMID: 25220718.
172. Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective Exploratory Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy with High-Dose Heart Exposure. J Thorac Oncol 9(10):1554-1560, 2014. PMID: 25521400.
173. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the optimal Radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 9(9):1398-1405, 2014. PMID: 25122435.
174. Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. Radiother Oncol 112(2):256-261, 2014. e-Pub 2014. PMID: 25108807.
175. Chang JY, Kestin LL, Barriger RB, Chetty IJ, Ginsburg ME, Kumar S, Loo BW Jr, Movsas B, Rimner A, Rosenzweig KE, Stinchcombe TE, Cm GM, Willers H.. ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent. Oncology 28(8):200882, 2014.
176. Zhuang H, Yuan Z, Chang JY, Wang J, Pang Q, Zhao L, Wang P. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol 9(6):882-885, 2014. PMID: 24828665.
177. Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, Wu X, Gu J. Telomere Length in Peripheral Blood Leukocytes and Lung Cancer Risk: A Large Case-Control Study in Caucasians. Cancer Res 74(9):2476-2486, 2014. e-Pub 2014. PMID: 24618342.
178. Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. J Thorac Dis 6(4):348-355, 2014. PMID: 24688779.
179. Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys 88(5):1120-1128, 2014. PMID: 24661665.
180. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus 27(2):168-175, 2014. e-Pub 2013. PMID: 23621168.
181. Li Y, Kardar L, Li X, Li H, Cao W, Chang JY, Liao L, Zhu RX, Sahoo N, Gillin M, Liao Z, Komaki R, Cox JD, Lim G, Zhang X. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys 41(2):021721, 2014. PMID: 24506612.
182. Zhu Z, Liu W, Gillin M, Gomez DR, Komaki R, Cox JD, Mohan R, Chang JY. Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: A secondary analysis of a phase II trial. Radiat Oncol 9(1):108, 2014. e-Pub 2014. PMID: 24886059.
183. Zhuang H, Zhao X, Zhao L, Chang JY, Wang P. Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Des Devel Ther 8:667-675, 2014. e-Pub 2014. PMID: 24936128.
184. Grant JD, Chang JY. Proton-Based Stereotactic Ablative Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer. Biomed Res Int 2014:389048, 2014. e-Pub 2014. PMID: 25136582.
185. Li H, Liu W, Park P, Matney J, Liao Z, Chang J, Zhang X, Li Y, Zhu RX. Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. J Appl Clin Med Phys 15(5):4810, 2014. e-Pub 2014. PMID: 25207565.
186. Zhang X, Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 12(8):1484-1491, 2013. PMID: 24389430.
187. Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer 82(2):252-259, 2013. e-Pub 2013. PMID: 24018022.
188. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, Mohan R, Rozner MA, Dougherty AH. Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors. Int J Radiat Oncol Biol Phys 87(3):570-575, 2013. PMID: 24074931.
189. McAvoy SA, Ciura KT, Rineer JM, Allen PK, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol 109(1):38-44, 2013. e-Pub 2013. PMID: 24016675.
190. Evans JD, Gomez DR, Chang JY, Gladish GW, Erasmus JJ, Rebueno N, Banchs J, Komaki R, Welsh JW. Cardiac (18)F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109(1):82-88, 2013. e-Pub 2013. PMID: 24016676.
191. Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG. Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer. Cancer 119(18):3402-3410, 2013. e-Pub 2013. PMID: 23798353.
192. Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly M, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-147, 2013. PMID: 23920393.
193. Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery?. Thorac Surg Clin 23(3):369-381, 2013. PMID: 23931020.
194. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non-Small Cell Lung Cancer in Never Smokers. Cancer Res 73(13):4028-4038, 2013. e-Pub 2013. PMID: 23704207.
195. Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86(4):665-670, 2013. e-Pub 2013. PMID: 23688815.
196. Pan T, Riegel AC, Ahmad MU, Sun X, Chang JY, Luo D. New weighted maximum-intensity-projection images from cine CT for delineation of the lung tumor plus motion. Med Phys 40(6):061901, 2013. PMID: 23718592.
197. Hou DL, Shi GF, Gao XS, Asaumi J, Li XY, Liu H, Yao C, Chang JY. Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma. Radiat Oncol 8(1):169, 2013.
198. Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-1319, 2013. e-Pub 2013. PMID: 23300016.
199. Kong FM, Lally BE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Langer CJ, Movsas B, Videtic GM, Willers H, Rosenzweig KE, Expert Panel on Radiation Oncology-Lung. ACR Appropriateness Criteria® Radiation Therapy for Small-Cell Lung Cancer. Am J Clin Oncol 36(2):206-213, 2013. PMID: 23511336.
200. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 31(7):895-902, 2013. e-Pub 2013. PMID: 23341526.
201. Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, and Yamashita H. Oligometastases/Oligo-Recurrence of Lung Cancer. Pulmonary medicine(438236), 2013.
202. Rosenzweig KE, Chang JY, Chetty IJ, Decker RH, Ginsburg ME, Kestin LL, Kong FM, Lally BE, Langer CJ, Movsas B, Videtic GM, Willers H. ACR Appropriateness Criteria Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent. J Am Coll Radiol 10(9):654-664, 2013. e-Pub 2013.
203. Welsh J, Amini A, Ciura K, Nguyen N, Palmer M, Soh H, Allen PK, Paolini M, Liao Z, Bluett J, Mohan R, Gomez D, Cox JD, Komaki R, Chang JY. Evaluating proton stereotactic body radio therapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim 38(4):442-447, 2013. PMID: 24200220.
204. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY. Adaptive/Nonadaptive Proton Radiation Planning and Outcomes in a Phase II Trial for Locally Advanced Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 84(5):1093-1100, 2012. e-Pub 2012. PMID: 22543217.
205. Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of five treatment strategies for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(5):1060-1070, 2012. e-Pub 2012. PMID: 22975611.
206. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting Radiation Pneumonitis After Stereotactic Ablative Radiation Therapy in Patients Previously Treated With Conventional Thoracic Radiation Therapy. Int J Radiat Oncol Biol Phys 84(4):1017-1023, 2012. e-Pub 2012. PMID: 22543216.
207. Zhang X, Fang B, Mohan R, Chang JY. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiother Oncol 105(2):250-257, 2012. e-Pub 2012. PMID: 23022172.
208. Quan EM, Chang JY, Liao Z, Xia T, Yuan Z, Liu H, Li X, Wages CA, Mohan R, Zhang X. Automated Volumetric Modulated Arc Therapy Treatment Planning for Stage III Lung Cancer: How Does It Compare With Intensity-Modulated Radio Therapy?. Int J Radiat Oncol Biol Phys 84(1):e69-76, 2012. PMID: 22901421.
209. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY. Positron Emission Tomography for Assessing Local Failure after Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 85(5):1558-1565, 2012. e-Pub 2012. PMID: 22572078.
210. Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY, Chang JY . The expression of HIF-1a in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep 39(2):2021-2029, 2012. e-Pub 2011. PMID: 21647551.
211. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY . Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 82(1):e91-97, 2012. e-Pub 2011. PMID: 21489716.
212. Grosshans DR, Boehling, NS, Palmer M, Spicer C, Erice R, Cox JD, Komaki R and Chang JY. Alternative Beam Arrangements for IMRT Planning in Patients with Carcinoma of the Distal Esophagus. Practical Radiation Oncology 2:41-45, 2012.
213. Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol 7(1):144, 2012. e-Pub 2012. PMID: 22929048.
214. Gomez DR, Niibe Y, Chang JY. Oligometastatic disease at presentation or recurrence for non-small cell lung cancer. Pulm Med 84(1):69-76, 2012. e-Pub 2012. PMID: 22900169.
215. Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 7(1):152, 2012. e-Pub 2012. PMID: 22963661.
216. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang JY, Maru D, Lee JH, Lee J, Ajani JA, Swisher SG. Salvage esophagectomy after Failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg 94(4):1126, 2012. e-Pub 2012.
217. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med 2012:261096, 2012. e-Pub 2012. PMID: 22966429.
218. Grosshans D, Boehling NS, Palmer M, Spicer C, Erice R, Cox JD, Komaki R, Chang JY . Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. Pract Radiat Oncol 2(1):41-5, 2012. e-Pub 2011. PMID: 24674035.
219. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Chang JY. A Prospective Evaluation of Staging and Target Volume Definition of Lymph Nodes by (18)FDG PET/CT in Patients with Squamous Cell Carcinoma of Thoracic Esophagus. Int J Radiat Oncol Biol Phys 81(5):e759-765, 2011. e-Pub 2011. PMID: 21470788.
220. Decker RH, Langer CJ, Rosenzweig KE, Chang JY, Gewanter RM, Ginsburg ME, Kong FM, Lally BE, Videtic GM, Movsas B. ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancer. Am J Clin Oncol 34(5):537-544, 2011. PMID: 21946673.
221. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91-96, 2011. e-Pub 2010. PMID: 20542388.
222. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, Swisher SG, Gillin M, Mohan R, Cox JD. Toxicity and Patterns of Failure of Adaptive/Ablative Proton Therapy for Early-Stage, Medically Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 80(5):1350-1357, 2011. e-Pub 2011. PMID: 21251767.
223. Register SP, Zhang X, Mohan R, Chang JY. Proton Stereotactic Body Radiation Therapy for Clinically Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 80(4):1015-1022, 2011. e-Pub 2010. PMID: 20615629.
224. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 117(13):3004-3013, 2011. e-Pub 2011. PMID: 21264827.
225. Peng Y, Vedam S, Chang JY, Gao S, Sadagopan R, Bues M, Balter P. Implementation of Feedback-Guided Voluntary Breath-Hold Gating for Cone Beam CT-Based Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol Phys 80(3):909-917, 2011. e-Pub 2011. PMID: 21470784.
226. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-Wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy. J Natl Cancer Inst 103(10):817-825, 2011. e-Pub 2011. PMID: 21483023.
227. Nguyen GH, Murph MM, Chang JY. Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. Cancers (Basel) 3(1):1232-1252, 2011. PMID: 21603589.
228. Ikushima H, Balter P, Komaki R, Hunjun S, Bucci MK, Liao Z, McAleer MF, Yu ZH, Zhang Y, Chang JY, Dong L. Daily Alignment Results of In-Room Computed Tomography-Guided Stereotactic Body Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys 79(2):473-480, 2011. e-Pub 2010. PMID: 20399032.
229. Gomez DR, Chang JY. Adaptive Radiation for Lung Cancer. J Oncol 2011, 2011. e-Pub 2010. PMID: 20814539.
230. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 117(20):4707-4713, 2011. e-Pub 2011. PMID: 21437893.
231. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology 1:52, 2011. e-Pub 2011. PMID: 22649768.
232. Shirvani SM and Chang JY. Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. Cancers 3:3432-3448, 2011.
233. Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78(5):1387-1393, 2010. e-Pub 2010. PMID: 20381271.
234. Gopal RS, Dubey S, Rosenzweig KE, Chang JY, Decker R, Gewanter RM, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non-Small-Cell Lung Cancer: expert panel on radiation oncology-lung. Int J Radiat Oncol Biol Phys 78(4):969-974, 2010. e-Pub 2010. PMID: 20813465.
235. Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 Esophageal Cancer After Neoadjuvant Therapy and Surgery: An Orphan Status. Ann Thorac Surg 90(3):884-890, 2010. e-Pub 2010. PMID: 20732513.
236. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces normal tissue doses compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB-non-small cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 77(2):357-366, 2010. e-Pub 2009. PMID: 19660879.
237. Gewanter RM, Rosenzweig KE, Chang JY, Decker R, Dubey S, Kong FM, Lally BE, Langer CJ, Lee HK, Movsas B. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. Curr Probl Cancer 34(3):228-249, 2010. PMID: 20541060.
238. Nelson C, Balter P, Morice RC, Bucci K, Dong L, Tucker S, Vedam S, Chang JY, Starkschall G. Evaluation of Tumor Position and PTV Margins Using Image Guidance and Respiratory Gating. Int J Radiat Oncol Biol Phys 76(5):1578-1585, 2010. e-Pub 2010. PMID: 20137865.
239. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):pii: e12402, 2010. e-Pub 2010. PMID: 20811626.
240. Yu W, Fu XL, Zhang YJ, Xiang JQ, Shen L, Jiang GL, Chang JY. GTV spatial conformity between different delineation methods by (18)FDG PET/CT and pathology in esophageal cancer. Radiother Oncol 93(3):441-446, 2009. e-Pub 2009. PMID: 19682760.
241. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?. Cancer 115(14):3233-3242, 2009. PMID: 19472405.
242. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. J Thorac Oncol 4(7):880-888, 2009. e-Pub 2009. PMID: 19458557.
243. Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 4(2):179-184, 2009.
244. Riegel AC, Chang JY, Vedam SS, Johnson V, Chi PC, Pan T. Cine Computed Tomography Without Respiratory Surrogate in Planning Stereotactic Radiotherapy for Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(2):433-441, 2009. e-Pub 2008. PMID: 18644683.
245. Vassiliev ON, Kry SF, Chang JY, Balter PA, Titt U, Mohan R. Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. J Appl Clin Med Phys 10(1):2880, 2009. e-Pub 2009. PMID: 19223837.
246. Sulman EP, Komaki R, Klopp AH, Cox JD, Chang JY. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol 4(1):5, 2009. PMID: 19183471.
247. Ezhil M, Vedam S, Balter P, Choi B, Mirkovic D, Starkschall G, Chang JY. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiat Oncol 4:4, 2009. PMID: 19173738.
248. Wu X, Lu C, Ye Y, Chang JY, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18(11):955-965, 2008. PMID: 18854777.
249. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967-971, 2008.
250. Gayed IW, Chang JY, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 3(8):858-864, 2008. PMID: 18670303.
251. Wagener M, Zhang X, Villarreal HG, Levy L, Allen P, Shentu S, Fang B, Krishnan S, Chang JY, Cheung MR. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. Oncol Rep 19(5):1071-1077, 2008.
252. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14(9):2813-2823, 2008.
253. Kennedy MP, Jimenez CA, Chang JY, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J 31(4):902-903, 2008.
254. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 3(2):177-186, 2008.
255. Qiao XY, Wang W, Zhou ZG, Gao XS, Chang JY. Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 70(2):396-402, 2008. e-Pub 2007. PMID: 17855004.
256. Nelson C, Balter P, Morice RC, Choi B, Kudchadker RJ, Bucci K, Chang JY, Dong L, Tucker S, Vedam S, Briere T, Starkschall G. A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. J Appl Clin Med Phys 9(4):2766, 2008.
257. Hui Z, Zhang X, Starkschall G, Li Y, Mohan R, Komaki R, Cox JD, Chang JY. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys 72(5):1385-1395, 2008. e-Pub 2008.
258. Britton KR, Starkschall G, Liu H, Chang JY, Bilton S, Ezhil M, John-Baptiste S, Kantor M, Cox JD, Komaki R, Mohan R.. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 73(1):94-102, 2008. e-Pub 2008.
259. Klopp AH, Chang JY, Tucker SL, Sulman EP, Balter PA, Liu HH, Bucci MK, Macapinlac HA, Komaki R, Cox JD. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69(5):1409-1416, 2007. e-Pub 2007. PMID: 17904303.
260. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69(2):350-357, 2007. e-Pub 2007. PMID: 17467922.
261. Zhu G, Cao X, Chang JY, Milas L, Wallace S, Li C. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol Rep 18(3)(3):645-651, 2007. PMID: 17671714.
262. Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 68(5):1349-1358(5):1349-1358, 2007. e-Pub 2007. PMID: 17446001.
263. Britton KR, Starkschall G, Tucker SL, Pan T, Nelson C, Chang JY, Cox JD, Mohan R, Komaki R. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 68(4):1036-1046, 2007. e-Pub 2007. PMID: 17379442.
264. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-785, 2007. e-Pub 2007. PMID: 17418967.
265. Liu HH, Balter P, Tutt T, Choi B, Zhang J, Wang C, Chi M, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang JY, Komaki R, Cox JD, Mohan R, Dong L. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 68(2):531-540, 2007. e-Pub 2007. PMID: 17398035.
266. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67:389-396, 2007.
267. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, Zhu XR, Mohan R, Dong L. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 67:906-914, 2007.
268. Nelson C, Starkschall G, Balter P, Morice RC, Stevens CW, Chang JY. Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys 67:915-923, 2007.
269. Takahashi N, Yang DJ, Kohanim S, Oh CS, Yu DF, Azhdarinia A, Kurihara H, Zhang X, Chang JY, Kim EE. Targeted functional imaging of estrogen receptors with (99m)Tc-GAP-EDL. Eur J Nucl Med Mol Imaging 34:354-362, 2007.
270. Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. J Thorac Oncol 6(6):526-531, 2006. PMID: 17409912.
271. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65(4):1087-1096, 2006. e-Pub 2006. PMID: 16682145.
272. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol 1(3):252-259, 2006. PMID: 17409865.
273. Chang JY, Zhang X, Komaki R, Cheung R, Fang B. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 64:1482-1494, 2006.
274. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Jr, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106:441-447, 2006.
275. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J, Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 47:1756-1762, 2006.
276. Nelson C, Starkschall G, Chang JY. The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume. Int J Radiat Oncol Biol Phys 65:573-586, 2006.
277. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24:4485-4491, 2006.
278. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66:117-125, 2006.
279. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Cgurueac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr., Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(6):548-582, 2006.
280. Wang H, Dong L, O'Daniel J, Mohan R, Garden AS, Ang KK, Kuban DA, Bonnen M, Chang JY, Cheung R. Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy. Phys Med Biol 50:2887-2905, 2005.
281. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res 11:6657-6668, 2005.
282. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11:3342-3348, 2005.
283. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol 32:S92-98, 2005.
284. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 11:2894-2898, 2005.
285. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77:247-253, 2005.
286. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61:656-664, 2005. PMID: 15708243.
287. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Jr, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60:427-436, 2004.
288. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Jr, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58:204-212, 2004. PMID: 14697440.
289. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1258-1267, 2004.
290. Yang DJ, Bryant J, Chang JY, Mendez R, Oh CS, Yu DF, Ito M, Azhdarinia A, Kohanim S, Edmund Kim E, Lin E, Podoloff DA. Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex. Anticancer Drugs 15:255-263, 2004.
291. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang JY, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following post-operative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9(6):476-484, 2003. PMID: 14740977.
292. Hung MC, Chang JY, Xing X. Preclinical and clinical study of HER-2/neu-targeting gene therapy. Adv Drug Deliv Rev 30:219-227, 1998.
293. Xing X, Zhang S, Chang JY, Tucker SD, Chen H, Huang L, Hung MC. Safety study and characterization of E1A liposome complex gene delivery protocol in an ovarian cancer model. Gene Therapy:1538-1544, 1998.
294. Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 14:561-568, 1997.
295. Chang JY, Xia W, Shao R, Hung MC. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene 13:1405-1412, 1996.
296. Hung MC, Matin A, Chang JY, Xing XM, Sorgi F, Huang L, Yu D. HER-2/neu-targeting gene therapy. Gene 159:65-71, 1995.
297. Chang JY, Yu D, Xia W, Hung MC. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 10:1947-1954, 1995.
298. Chang JY, Mukhodahyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4:451-460, 1993.
299. Georges RN, Mukhopadhyay T, Chang JY, Nancy Yen, Roth JA. Prevention of orthotopic human lung cancer growth by intratracheal installation of a retroviral antisense K-ras construct. Cancer Res 53:1743-1746, 1993.
300. Tang ZY, Liu KD, Fan Z, Lu JZ, Chang JY, Xi H, Schroder CH, Arosio P. A decade's studies on the immunotargeting therapy of hepatocellular carcinoma. Antibody, Immunoconjugates, and Radiopharm 6:155-165, 1993.
301. Chang JY , Tang ZY, Xie H, Yuan AN, Zhao HY, Lu JZ. Imaging and therapy of human hepatocellular carcinoma with radiolabeled monoclonal antibody. J Exp Clin Cancer Res 10:243-252, 1991.

Invited Articles

1. Chang JY, Verma V. Could the Clinical Target Volume be Omitted for Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer in the Modern Era?. Translational Lung Cancer Research 10:5-8, 2021.
2. Verma V and Chang JY. Controversies in Dose-Escalation for Locally Advanced Non-Small Cell Lung Cancer and the Role of Proton Beam Therapy. J Thorac Dis 10:S1124-1126, 2018.
3. De Ruysscher D, Chang JY. Clinical controversies: proton therapy for thoracic tumors. Semin Radiat Oncol 23(2):115-119, 2013. PMID: 23473688.
4. Shirvani SM, Roth JA, Chang JY. Can stereotactic body radiation therapy (SBRT) in early stage tumors produce comparable success as surgery?. Thoracic Surgery Clinic 23(3):369-381, 2013.
5. Selek U, Chang JY. Evolution of modern-era radiotherapy strategies for unresectable advanced non-small cell lung cancer. Lung Cancer Management 2(3):213, 2013.
6. Shirvani SM, Chang JY. Proton therapy for non–small cell lung cancer: current evidence and future directions. Thoracic Cancer 3:99-108, 2012.
7. Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer 30(5):315-326, 2011. PMID: 21527064.
8. Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chin J Cancer 29(10):843-854, 2010. e-Pub 2010. PMID: 20868553.
9. Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol 20(3):171-177, 2010. PMID: 20652085.
10. Chang JY, Roth JA. Stereotactic body radiation therapy for stage I NSCLC. Thoracic Surgery Clinics 17:251-259, 2007.
11. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep 7:255-259, 2005. PMID: 15946583.

Editorials

1. Verma V, Chang JY. Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. J Thorac Dis 10(11):21-24, 2018.
2. Barton MK for Cancer 10.1002/cncr.30693 (Chang JY). Encouraging long-term outcomes reported in patients with stage I NSCLC treated with stereotactic ablative radiotherapy. CA: A Cancer Journal for Clinicians 67(5):349-350, 2017.
3. Selek U, Chang JY. Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. J Thorac Dis 8(7):1394, 2016.
4. Tang C, Chang JY. PD-L1 expression in lung cancer. J Thorac Dis 8(11):3053-3055, 2016.
5. Chang JY, De Ruysscher D. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. J Thorac Dis 6(4):285-286, 2014. PMID: 24688773.
6. Chang JY. Oncology scan-promising strategies for the treatment of locally-advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):1-4, 2013.
7. Chang JY. Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges. J Thorac Dis 3(3):144-146, 2011. PMID: 22263079.
8. Loo BW, Chang JY, Dawson L, Kavanagh BD, Koong A, Senan S, Timmerman R. Stereotactic ablative radiotherapy: What's in a name?. Practical Radiation Oncology 1:38-39, 2011.
9. Chang JY. Telomerase: a potential molecular marker and therapeutic target for cancer. J Surg Oncol 87:1, 2004. PMID: 15112252.

Abstracts

1. Xiang Z, Hess K, Zhang X, Liang S, Chang JY. A Dosimetric Model for Predicting Radiation Pneumonitis After Stereotactic Ablative Radiotherapy for Stage I Non-small Cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 84(3S):S557, 2012.

Book Chapters

1. Ahuja J, Strange CD, Chang JY, Mehran RJ, Truong MT. Pleural Tumors. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier: Philadelphia, 2022.
2. Gomez D, Li H, Zhang X, Chang JY, Liao Z, Lin S. Lung cancer. In: Proton therapy. Elservier: Philadephia, 2021.
3. Shirvani SM and Chang JY. Charged particles in stereotactic radiosurgery. In: Principles and Practice of Stereotactic Radiosurgery. 2nd. Springer, 2015.
4. Chang JY and Cox JD. Proton Therapy. In: Lung Cancer. 4. Blackwell, 338-352, 2014.
5. Chang JY. Cancer of the lung. In: Technical basis of radiation therapy: Practical clinical applications. Fifth edition. Springer, 755-775, 2012.
6. Chang JY, Shirvani SM, Loo BW, Lamond JP, Slotman B, Nagata Y. Primary lung cancer. In: Stereotactic Body Radiation Therapy. Springer: New York, 137-162, 2012.
7. Truong MT, Gomez D, Chang JY and Mehran RJ. Pleural tumors. In: Oncologic Imaging: a muitidisciplinary approach. Elsevier, 79-93, 2012.
8. Lin SH and Chang JY. Lung cancer. In: Decision making in Radiation Oncology. Springer: New York, 261-328, 2011.
9. Shirvani SM and Chang JY. Hypofractionated proton therapy in the treatment of non-small cell lung cancer. In: Hypofractionation: scientific concepts and clinical experiences. Lumi Text Publishing, 339-353, 2011.
10. Chang JY. Thorax. In: Uncertainties in external beam radiation therapy. Medical Physics Publishing, 575-592, 2011.
11. Christodouleas JP and Chang JY. Early stage non-small cell lung cancer. In: Radiation Oncology: a question-based review. Lippincott Williams and Wilkins: Phyladelphia, 199-209, 2011.
12. Chang JY and Komaki R. Proton therapy in lung and thoracic cancers. In: Radiation Medicine Rounds: Proton Therapy. Demos Medical Publishing: New York, 523-537, 2010.
13. Chang JY, Smith A, Cox JD. Proton therapy. In: Lung Cancer. 3. Blackwell Publishing Ltd, 271-282, 2008.
14. Chang JY, Komaki R, Roth JA, Herbst r, Cox JD. Image guidance of combined modality management of NSCLC. In: Image-guided radiation therapy for lung cancer. Informa, 1-18, 2008.
15. Chang JY. Image-guided radiotherapy guidelines and techniques for NSCLC. In: Image-guided radiation therapy for lung cancer. Informa, 19-38, 2008.
16. Chang JY, Balter P, Komaki R. Stereotactic body radiation therapy (SBRT) in stage I, selective stage II and isolated peripheral recurrent NSCLC. In: Image-guided radiation therapy for lung cancer. Informa, 93-102, 2008.
17. Chang JY, Mohan R, Cox JD. Image-guided proton radiotherapy. In: Image-guided radiation therapy for lung cancer. Informa, 127-139, 2008.
18. Chang JY, Bradley J, Govindan R, Komaki R. Lung. In: Principles and Practice of Radiation Oncology. 5th. 5th Edition. Lippincott Williams &Wilkin, 1076-1108, 2008.
19. Janjan NA, Strom E, Perkins G, Ha, C, Chang JY. Effects of radiation on the heart. In: Cancer and the Heart. BC Decker Inc, 75-113, 2006.
20. Onn A, Vaprociyan A, Chang JY, Komaki R, Roth JA, Herbst RS. Cancer of the lung. In: Cancer Medicine. 27. BC Decker Inc, 1179-1225, 2006.
21. Komaki R, Chang JY, Liao Z, Cox JD, Mason KA, Milas L. Radioprotectors and chemoprotectors in the management of lung cancer. In: Medical Radiology-Radiation Oncology: Advances in radiation Oncology in lung cancer. Springer-Verlag, 123-134, 2004.
22. Chang JY, Mukhopadhyay T, Georges RN, Roth JA. Molecular targeting of cancer: retroviral vector-mediated antisense nucleic acid therapy. In: Gene Therapy From Laboratory to the Clinic. World Scientific Publishing Co: New Jersey, 70-106, 1994.
23. Chang JY. Immunotherapy of human hepatocellular carcinoma with lymphokine-activated killer cells and interleukin-2. In: The Advance in Primary Liver Cancer Research. 26. Shanghai Medical University Press, 263-272, 1990.

Books (edited and written)

1. Xia, T, Chang JY, Wang L. Stereotactic Ablative Radiotherapy in Cancer. People's Medical Publishing House Co., LTD: Beijing, 2022.
2. Cai J, Chang JY, FF Yin. Principles and Practice of Image-guided Radiotherapy in Lung Cancer. Ed(s) Cai J, Chang JY, FF Yin. Talor and Francis Group: USA, 2018.
3. Roth JA, Hong WK, Komaki R, Tsao A, Chang JY. Lung Cancer. Ed(s) Roth JA, Hong WK, Komaki R, Tsao A, Chang JY. Blackwell, 2014.
4. Cox JD, Chang JY, Komaki R. Image-guided radiation therapy for lung cancer. Taylor and Francis Group, 2008.

Letters to the Editor

1. Chang JY. The Stars is still shining in the sky. Int J Radiat Oncol Biol Phys, 2018.